Meso-substituted porphyrins

1. Compounds of general formula (I)

wherein

R is the following group of formula (II)

wherein

X is selected from the group consisting of O, S, CH 2 , COO, CH 2 CO, O(CH 2 ) 2 O, O(CH 2 ) 3 O and N;

Z is selected from between N and CH 2 N;

Y is selected from aliphatic groups, linear or branched, saturated or unsaturated, having from 1 to 10 carbon atoms, and phenyl, or Y forms with Z a saturated or unsaturated heterocycle, selected from the group consisting of: morpholine, piperidine, pyrimidine, piperazine, pyrrolidine, pyrroline, aniline, julolidine (2,3,6,7-tetrahydro-1H,5H-pirido[3,2,1-Ij]quinoline, and substituted forms thereof;

R 4 and R 5 , equal or different from each other, are selected from H and alkyl groups having from 1 to 3 carbon atoms, or they form with the Z group a saturated or unsaturated heterocycle, selected from the group consisting of: morpholine, piperidine, pyrimidine, piperazine, pyrrolidine, pyrroline, aniline, julolidine (2,3,6,7-tetrahydro-1H,5H-pirido[3,2,1-Ij]quinoline), and substituted forms thereof;

R 6 is selected from H and aliphatic groups, linear or branched, saturated or unsaturated, having from 1 to 5 carbon atoms, comprising a saturated heterocycle selected from the group consisting of:

morpholine, piperidine, piperazine, pyrrolidine, and substituted forms thereof;

d, m, and n, equal of different from each other, are selected from 0 and 1;

v and s, equal or different from each other, are integers comprised between 1 and 3;

R 1 is selected from H and a group of formula (III)

wherein

G is selected from H and P— (CH 2 ) 1 —(W) f -J, wherein

P is selected from the group consisting of O, CH 2 , CO 2 , NHCONH and CONH;

l is an integer comprised between 0 and 5;

W is selected from the group consisting of O, CO 2 , CONH and NHCONH;

f is selected from between 0 and 1;

J is H or an alkyl group (CH 2 ) q —CH 3 , wherein q is an integer comprised between 0 and 20;

R 2 and R 3 , equal or different from each other, are selected from between R and R 1 , wherein R and R 1 are defined as above,

M is chosen from 2H and a metal selected from the group consisting of Zn, Mg, Pt, Pd, Si(OR 7 ) 2 , Ge(OR 7 ) 2 and AlOR 7 , wherein R 7 is chosen from between H and C1-C15 alkyl,

and pharmaceutically acceptable salts thereof,

with the exception of the following compounds:

a) compound of formula (I) wherein M is 2H, R 1 ═R 3 ═H, R═R 2 is a group of formula (II) in which s is 1, X is O, Y is (CH 2 ) 3 , v is 1, Z is N, n=d=l, m is 0, and R 4 ═R 5 ═H; and

b) compound of formula (I) wherein M is 2H, R 1 ═R 3 ═H, R═R 2 is a group of formula (II) in which s is 1, X is O, Y is (CH 2 ) 3 , v is 1, Z is N, n=d=1, m is 0, R 4 and R 5 form with Z a phthalimido group.

2. Compounds of general formula (I) according to claim 1 , in which the group R comprises at least one substituent bearing tertiary or quaternary nitrogen.

3. Compounds of general formula (I) according to claim 1 , wherein the group

is selected from the group consisting of:

4. Compounds of general formula (I) according to claim 1 , wherein R 6 is selected from aliphatic groups, linear or branched, saturated or unsaturated, having from 1 to 5 carbon atoms, substituted with alkylamine or alkylammonium groups having alkyl chains comprising from 1 to 5 carbon atoms.

5. Compounds of general formula (I)

wherein

R is the following group of formula (II)

wherein

X is selected from the group consisting of O, S, CH 2 , COO, CH 2 CO, O(CH 2 ) 2 O, O(CH 2 ) 3 O and N;

Z is selected from between N and CH 2 N;

Y is selected from aliphatic groups, linear or branched, saturated or unsaturated, having from 1 to 10 carbon atoms, and phenyl or Y forms with Z a pyridine or substituted pyridine heterocycle;

R 4 and R 5 , equal or different from each other, are selected from H and alkyl groups having from 1 to 3 carbon atoms, or they form with the Z group a pyridine or substituted pyridine heterocycle;

R 6 is selected from H and aliphatic groups, linear or branched, saturated or unsaturated, having from 1 to 5 carbon atoms, or comprising a saturated heterocycle selected from the group consisting of:

morpholine, piperidine, piperazine, pyrrolidine, and substituted forms thereof;

d, m, and n, equal of different from each other, are selected from 0 and 1;

v and s, equal or different from each other, are integers comprised between 1 and 3;

R 1 is selected from H and a group of formula (III)

wherein

G is selected from H and P— (CH 2 ) 1 — (W) f -J, wherein

P is selected from the group consisting of O, CH 2 , CO 2 , NHCONH and CONH;

l is an integer comprised between 0 and 5;

W is selected from the group consisting of O, CO 2 , CONH and NHCONH;

f is selected from between 0 and 1;

J is H or an alkyl group (CH 2 ) q —CH 3 , wherein q is an integer comprised between 0 and 20;

R 2 and R 3 , equal or different from each other, are selected from between R and R 1 , wherein R and R 1 are defined as above,

M is chosen from 2H and a metal selected from the group consisting of Zn, Mg, Pt, Pd, Si(OR 7 ) 2 , Ge(OR 7 ) 2 and AlOR 7 , wherein R 7 is chosen from between H and C1-C15 alkyl,

and pharmaceutically acceptable salts thereof,

with the exception of the following compounds:

a) compound of formula (I) wherein M is 2H, R 1 ═R 3 ═H, R═R 2 is a group of formula (II) in which s is I, X is O, Y is (CH 2 ) 3 , v is 1, Z is N, n=d=1, m is 0, and R 4 ═R 5 ═H; and

b) compound of formula (I) wherein M is 2H, R 1 ═R 3 ═H, R═R 2 is a group of formula (II) in which s is I, X is O, Y is (CH 2 ) 3 , v is I, Z is N, n=d=1, m is O, R 4 and R 5 form with Z a phthalimido group.

6. Compounds of general formula (I) according to claim 5 , wherein the group

is selected from the group consisting of:

7. Compounds of general formula (I)

wherein

R is the following group of formula (II)

wherein

X is selected from the group consisting of O, S, CH 2 , COO, CH 2 CO, O(CH 2 ) 2 O, O(CH 2 ) 3 O and N;

wherein the group

is selected from the group consisting of:

v and s, equal or different from each other, are integers comprised between 1 and 3;

R 1 is selected from H and a group of formula (III)

wherein

G is selected from H and P—(CH 2 ) 1 —(W) f — J, wherein

P is selected from the group consisting of O, CH 2 , CO 2 , NHCONH and CONH;

l is an integer comprised between 0 and 5;

W is selected from the group consisting of O, CO 2 , CONH and NHCONH;

f is selected from between 0 and 1;

J is H or an alkyl group (CH 2 ) q —CH 3 , wherein q is an integer comprised between 0 and 20;

R 2 and R 3 , equal or different from each other, are selected from between R and R 1 , wherein R and

R 1 are defined as above,

M is chosen from 2H and a metal selected from the group consisting of Zn, Mg, Pt, Pd, Si(OR 7 ) 2 , Ge(OR 7 ) 2 and AlOR 7 , wherein R 7 is chosen from between H and C1-C15 alkyl,

and pharmaceutically acceptable salts thereof.

8. Compounds of general formula (I) according to claim 1 , selected from the group consisting of: 5,10,15-tris-[4-(2-N,N,N-trimethylammoniumethoxy)-phenyl]-20-[(4-decyloxy)-phenyl]porphyrin triiodide,

5,10,15-tris-[4-(2-N,N,N-trimethylammoniumethoxy)-phenyl]-20-[(4-decyloxy)-phenyl]porphyrinate zinc (II) triiodide,

5,10,15-tris-[4-(2-N,N-dimethylaminoethoxy)phenyl]-20-[(4-decyloxy)phenyl]porphyrin],

5,10,15-tris-[4-(2-N,N-dimethylaminoethoxy)-phenyl]-20-[(4-decyloxy)phenyl]porphyrinate zinc (II),

5,10,15-tris-{[4-(N-methylpiperidin-4-yl)oxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin,

5,10,15-tris-{[4-(N,N-dimethylpiperidin-4-ium)oxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-[3-(2-morpholin-4-ylethoxy)phenyl]-20-[(4-decyloxy)phenyl]porphyrin,

5,10,15-tris-{[3-(2-methylmorpholin-4-ium)ethoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-{4-[4-(N,N-dimethylamino)phenoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin,

5,10,15-tris-{4-[4-(N,N,N-trimethylammonium)phenoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-{4-[3-(N,N-dimethylamino)phenyl]thiophenyl}-20-[(3-undecyloxy)phenyl]porphyrin,

5,10,15-tris-{4-[3-(N,N,N-trimethylammonium)phenyl]thiophenyl}-20-[(4-undecyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-[3-(3-N,N-dimethylaminopropoxy)phenyl]-20-[(3-undecyloxy)phenyl]porphyrin,

5,10,15-tris-[3-(3-N,N,N-trimethylammoniumpropoxy)phenyl]-20-[(3-undecyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-{4-[4-(N,N-dimethylamino)butoxy]phenyl}-20-[(4-undecyloxy)phenyl]porphyrin,

5,10,15-tris-{4-[4-(N,N,N-trimethylammonium)butoxy]phenyl}-20-[(4-undecyloxy)phenyl]porphyrin triiodide,

5-{4-{2,4,6-tris-[(dimethylamino)methyl]phenoxy}phenyl}-10,15,20-tris-[(4-decyloxy)phenyl]porphyrin,

5-{4-{2,4,6-tris-[(trimethylammonium)methyl]phenoxy}phenyl}-10,15,20-tris-[(4-decyloxy)phenyl]porphyrin triiodide,

5-{3-[2-(dimethylamino)]-1-{[(dimethylamino)methyl]ethoxy}phenyl}-10,15,20-tris-[(3-decyloxy)phenyl]porphyrin,

5-{3-[2-(trimethylammonium)]-1-{[(trimethylammonium)methyl]ethoxy}phenyl}-10,15,20-tris-[(3-decyloxy)phenyl]porphyrin diiodide,

5,10,15-tris-{4-[3-(diethylamino)propoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin,

5,10,15-tris-{4-[3-(trimethylammonium)propoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-[4-(2-aminoethoxy)phenyl]-20-[(4-decyloxy)phenyl]porphyrin,

5,10,15-tris-{[4-(2-trimethylammonium)ethoxy]phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5,10,15-tris-{{[4-(N,N,N-trimethylammonium)phenoxy]carbonyl}phenyl}-20-[(4-decyloxy)phenyl]porphyrin triiodide,

5-{4-{{2-(trimethylammonium)-1-[(trimethylammonium)methyl]ethoxy}carbonyl}phenyl}-10,15,20-tris-[(3-decyloxy)phenyl]porphyrin diiodide,

5,15-bis-[3-(3-N,N,N-trimethylammoniumpropoxy)phenyl]porphyrin diiodide,

5,15-bis-[4-(2-piperidin-1-ylethoxy)phenyl]porphyrin,

5,15-bis-[4-(2-N-methylpiperidin-1-iumethoxy)phenyl]porphyrin diiodide,

5,15-bis-[4-(3-N,N-dimethylaminopropoxy)phenyl]-10,20-bis-[(3-decyloxy)phenyl]porphyrin,

5,15-bis-[4-[3-N,N,N-trimethylammoniumpropoxy)phenyl]-10,20-bis-[(3-decyloxy)phenyl]porphyrin diiodide,

5,15-bis 4-{[2-(N,N-dimethylamino)ethylthio]phenyl}porphyrin,

5,15-bis-{4-[2-(N,N,N-trimethylammonium)ethylthio]phenyl}porphyrin diiodide,

5,15-bis-{4-{2-[3-(trimethylammonium)phenoxy]ethoxy}phenyl}porphyrin diiodide,

5,15-bis-{4-[2-[3-(N,N,N-trimethylammonium)phenyl]-2-oxoethyl}-10,20-bis-[(3-decyloxy)phenyl]porphyrin diiodide,

5,15-bis-[3-(3-N,N,N-trimethylammoniumpropoxy)phenyl]porphyrinate zinc(II) diiodide,

5,15-bis-[3-(3-N,N-dimethylaminopropoxy)phenyl]porphyrinate zinc(II),

5,15-bis-[4-(4-N,N,N-trimethylammoniumphenoxy)phenyl]porphyrin diiodide,

5,15-bis-[4-(4-aminophenoxy)phenyl]porphyrin,

5,15-bis-[3-(4-N,N-dimethylaminophenoxy)phenyl]porphyrin,

5,15-bis-[3-(4-N,N,N-trimethylammoniumphenoxy)phenyl]porphyrin diiiodide,

5,15-bis-[3-(4-N,N-dimethylaminophenyl)thiophenyl]porphyrin,

5,15-bis-[3-(4-N,N,N-trimethylammoniumthiophenoxy)phenyl]porphyrin diiiodide,

5,15-bis-4-[3-(N,N-dimethylaminophenoxy)phenyl]-10,20-bis-[(4-decyloxy)phenyl]porphyrin,

5,15-bis-4-[3-(N,N,N-trimethylammoniumphenoxy)phenyl]-10,20-bis-[(4-decyloxy)phenyl]porphyrin diiodide,

5,10,15-tris-{4-[4-(N,N-dimethylamino)butoxy]phenyl]-20-[(4-undecyloxy)phenyl]porphyrinate zinc(II),

5,10,15-tris-{4-[4-(N,N,N-trimethylammonium)butoxy]phenyl}-20-[(4-undecyloxy)phenyl]porphyrinate zinc(II) triiodide,

5,15-bis-[4-(2-piperidin-1-ylethoxy)phenyl]porphyrinate zinc(II), and

5,15-bis-[4-(2-N-methylpiperidin-1-iumethoxy)phenyl]porphyrinate zinc(II) diiodide.

9. Pharmaceutical compositions comprising as the active principle at least a compound of general formula (I) as defined in claim 1 in combination with pharmaceutically acceptable excipients and/or diluents.

10. A method of sterilizing wounds, comprising administering to a patient in need of such a treatment an effective amount of at least a compound of general formula (I) as defined in claim 1 , and thereafter irradiating the patient with light of appropriate wavelength.